Dupilumab (Sanofi) cemented its position as the top-selling inflammatory illness medication with its first-in-class IL-4Rα antagonist. In 2024, it generated $14.179 billion in sales (23% YoY growth).

Please provide your email address to receive an email when new articles are posted on . Dupilumab and mepolizumab are the only FDA-approved biologics for adults with COPD and an eosinophilic phenotype ...

Understand Parkinson's disease, its symptoms, and the crucial role of clinical trials in treatment and research, especially for Black Americans.